Lupin Limited’s subsidiary, VISUfarma B.V., has secured exclusive rights to market the presbyopia treatment YUVEZZI in Europe and the UK. The deal, valued at up to €75 million, aims to expand the company's vision care portfolio. Investors may monitor the upcoming regulatory timelines and commercial execution in these new markets.
Lupin Limited has announced that its wholly-owned subsidiary, VISUfarma B.V., has entered into an exclusive licensing agreement to commercialize the ophthalmic solution YUVEZZI in the European Union, the United Kingdom, Switzerland, Norway, and Iceland. This move is part of the company's broader strategy to strengthen its vision care franchise by introducing new specialized treatments.
Financial Structure of the Agreement
The licensing agreement grants VISUfarma the rights to handle regulatory approvals, marketing, distribution, and sales for YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) in the specified territories. The financial arrangement involves an initial strategic investment of €20 million via a Simple Agreement for Future Equity (SAFE) instrument in Visus Therapeutics, the developer of the drug.
The total value of the deal is capped at €75 million. Beyond the initial investment, the agreement includes up to €55 million in potential payments linked to reaching specific regulatory and commercial milestones. Additionally, Visus Therapeutics and its parent entity, Tenpoint Therapeutics Holding Ltd, will receive tiered royalties based on the net sales of the product.
Product Context and Market Outlook
YUVEZZI is a once-daily, dual-agent eye drop designed to treat presbyopia, a common condition where adults gradually lose the ability to focus on near objects. The product has already received approval from the U.S. FDA, which may support the company’s case as it seeks regulatory clearances in European markets.
While the U.S. approval is a positive reference point, the drug must still navigate the specific regulatory requirements and approval processes within each European country. The success of this investment will depend on how effectively the company can manage these regulatory hurdles and gain market share in a segment that faces competition from existing treatments.
Investor Monitorables
Investors may keep track of the progress in obtaining regulatory approvals across the European territories, as this will determine the timeline for the first commercial launch. The company’s ability to successfully execute the product rollout and manage the associated costs will be important factors in determining the return on this €20 million strategic investment. On the day of the announcement, Lupin shares were trading around ₹2,221.00.